

Security Health Plan policy review – Policies effective September through November 2019

Security Health Plan reviews medical policies on a monthly basis. Medical policies are found in the provider section of the Plan's public website. As we review and develop clinical criteria for our policies, providers with particular professional knowledge or clinical expertise on certain subjects are invited to provide input and opinions. Click on [policies web page](#) for more information including past monthly policy reviews.

Policy changes effective Sept. 1, 2019

Policies reviewed with changes made to medical criteria:

- Complementary/Alternative Medicine
- Experimental/Investigational
- Intrastromal Corneal Rings Segments
- Spinal Cord Stimulation
- Vagus Nerve Stimulation for Epilepsy and Depression
- Zika virus

Policies reviewed with no changes made to medical criteria:

- Genetic Testing
- Home, outpatient and inpatient chemotherapy
- Maze Procedure

Policy changes effective Oct. 1, 2019

Policies reviewed with changes made to medical criteria:

- Lung Volume Reduction System
- Septoplasty/Rhinoplasty
- Sleep Studies
- Synagis

Policies reviewed with no changes made to medical criteria:

- Medicare Advantage Skilled Nursing Facility Coverage Criteria
- Private Duty Nursing Duty
- Repetitive Transcranial Magnetic Stimulation
- Swing Bed

New Policies

- Spravato
- Zolgensma

Retired Policies

- Medicare Advantage Part C Drug Bundled Medication

Policy changes effective Nov. 1, 2019

Policies reviewed with changes made to medical criteria:

- Back Surgical Procedures for Lumbar Spinal Level - Inpatient and Outpatient Settings
- Eye Movement Desensitization and Reprocessing (EMDR)
- Left Atrial Appendage Closure to Reduce the Risk of Stroke
- Mitraclip Procedure
- Experimental/Investigational

Policies reviewed with no changes made to medical criteria:

- Ambulance: Land and Air Transportation
- Cellular Therapies
- Home Health Care- Medicare Advantage
- Medicare Advantage Chiropractor
- Takhzyro® (lanadelumab-flyo)

Retired Policies

- Intravenous Immune Globulins (immune globulin) - home infusion
- IV Antibiotic/Antifungal Prior Authorization Policy
- C1 esterase inhibitor (Haegarda®)